REDX PHARMA has denied it is currently in the process of listing in the US following a report in The Times.

The Cheshire-based company, which trades on the London Stock Exchange's AIM, added it is also not in the process of listing in any other jurisdiction.

The business said its board "continues to consider all financing and other strategic options to extend the cash runway in the best interests of all shareholders" The report comes after Redx Pharma signed a deal worth $880m with a Nasdaq-listed US counterpart.

In a statement, the company rejected the validity of a Times article "stating that the Company is 'eyeing' a US listing."

"Redx wishes to clarify that it is not currently in any process relating to a listing in the US, nor any other jurisdiction."

In May 2023, a planned $425m merger between the drug developer and a US counterpart was called off.

(c) 2024 City A.M., source Newspaper